[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].

Abstract

OBJECTIVE:

To evaluate the safety and efficacy of antiplatelet therapy of ticagrelor on patients suffering from acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

METHODS:

In the study, 96 patients suffering from acute ST segment elevation myocardial infarction onset within 12 h undergoing primary percutaneous coronary intervention from May to October in 2013 were randomly divided into ticagrelor group (n=48) and clopidogrel group (n=48) by using the method of random number table. Ticagrelor and clopidogrel antiplatelet treatment were used before and after operation. Their baseline data, coronary artery disease characteristics, platelet count, adenosine diphosphate(ADP)-induced platelet inhibition rate by thrombelastograph after 5 days of treatment, the major adverse cardiovascular events of the follow up for 6 months and bleeding complications were observed and compared in the two groups.

RESULTS:

The differences between the two groups of patients with their baseline data, the features of coronary artery lesions, platelet count before and after 5 days of treatment had no statistical significance (P>0.05). ADP induced platelet inhibition rate [(80.2±10.7)%] after 5 days of treatment in ticagrelor group was significantly higher than that in clopidogrel group [(75.3±12.1)%, P<0.05]. The two groups of patients were followed up for 6 months, 8 cases of major adverse cardiovascular events occurred in clopidogrel group, 2 cases of major adverse cardiovascular events occurred in ticagrelor group, and there was significant difference between the two groups (P<0.05). The two groups (7 cases of 48 patients in ticagrelor group vs. 3 cases of 48 patients in clopidogrel group) had no statistically significant difference in bleeding complications (P>0.05).

CONCLUSION:

Antiplatelet therapy of ticagrelor on patients suffering from acute ST segment elevation myocardial infarction undergoing emergency PCI has good efficacy and safety.

• Authors: Jing-gang Xia, Yang Qu, Shao-dong Hu, Ji Xu, Chun-lin Yin, Dong Xu
• Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences (Beijing Da Xue Xue Bao Yi Xue Ban) Vol. 47 Issue 3 Pg. 494-8 (Jun 18 2015) ISSN: 1671-167X [Print] China
• PMID: 26080882 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel
• Ticagrelor
• Adenosine
• Ticlopidine

Topics

• Adenosine (analogs & derivatives, pharmacology)
• Clopidogrel
• Follow-Up Studies
• Humans
• Myocardial Infarction (drug therapy, surgery)
• Percutaneous Coronary Intervention
• Platelet Aggregation Inhibitors (pharmacology)
• Ticagrelor
• Ticlopidine (analogs & derivatives, pharmacology)